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We retrospectively reviewed 107 diabetic patients who received a split thickness skin graft (STSG) for
treatment of a non-healing diabetic foot or leg ulcer to describe healing times based on patient characteristics,
comorbidities or complications. The minimum follow-up was 6 months from the time of STSG application.
The mean time to healing among all patients was 5.1 weeks (3 to 16 weeks). The mean healing time for
patients with complications was 12.0 weeks (10 to 16 weeks) while the mean healing time for those without
complications was 4.9 weeks (3 to 10 weeks). Overall complication rate was 2.8%. Patients with a STSG take
of less than 95% had a mean healing time of 7.9 weeks compared to 4.8 weeks for those with a STSG take of
100% (pB0.001). The use of autologous STSG for treatment of non-healing diabetic foot and leg wounds is a
viable method for soft tissue closure and may present a low complication rate and a satisfactory rate of
healing.
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F
oot and leg ulcers are the leading cause of
hospitalization in patients with diabetes mellitus
and precede approximately 7080% of all diabetic-
related amputations (1, 2). Timely healing and closure is
critical to reducing the cost and morbidity associated
with chronic diabetic lower extremity wounds (35). Split
thickness skin grafts (STSG) are awell-known and widely
accepted method for soft tissue coverage of open wounds
(6). Historically, this technique has had a significant role
in burn wounds and plastic surgery reconstruction, but
has also been used successfully in the treatment of
chronic diabetic foot ulcers (79). There are a vast
number of wound care products and synthetic grafts
available to the clinician today, but STSG remain the gold
standard and may be considered a first-line treatment for
lower extremity wounds associated with diabetes. Despite
its common indications, there have been few large studies
assessing the use of STSG as a modality for treatment of
diabetic foot and leg wounds. Furthermore, few papers
have examined the effect of individual patient risk factors
on the healing time of STSG in the diabetic population.
The aim of this retrospective review was to study the
clinical use of STSG in a diabetic population and also
identify any risk factors that may affect healing time or
lead to complications.
Patients and methods
Following approval by our institutional review board, the
medical charts of patients who received STSG for
treatment of foot and leg ulcers between 2002 and 2010
were identified and retrospectively reviewed. Inclusion
criteria included those patients who had a documented
history of diabetes mellitus and an ulceration of the foot
or leg distal to the tibial tuberosity. Patients were
excluded from the study if they did not have a history
of diabetes mellitus and/or less than 6 months follow up
from the time of the application of the STSG. Patients
with weight-bearing plantar ulcers were also excluded.
A total of 183 patients received STSG treatment by
the primary author during the selected time frame.
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exclusion criteria. One hundred seven (n107) met the
inclusion criteria and were included in the study. In-
formation regarding comorbidities and potential risk
factors for healing was also collected from each patient’s
medical record including age, history of smoking, history
of alcohol use, history of intravenous (IV) drug use,
wound size, rheumatoid arthritis, end-stage renal
disease, cardiac disease (coronary artery disease or
congestive heart failure), peripheral vascular disease
(PVD), history of fracture and history of Charcot
neuroarthropathy.
Prior to application of the STSG, all patients under-
went conservative local wound care with or without
negative-pressure wound therapy in an attempt to
promote a uniform granular wound bed with minimal
wound exudate, fibrin, or slough. STSG application was
delayed if there were any local signs of infection,
malodor, purulent drainage, or edema. No STSG were
applied directly over exposed bone, joint capsule or
tendon. Any patient with questionable peripheral vascu-
lar status was referred to vascular surgery for workup and
cleared prior to surgery. All STSG were performed in an
operating room setting under either general or local
regional anesthesia. Surgical preparation of the wound
was achieved by sharp or mechanical debridement of all
non-viable tissue from the wound bed and wound edges
in a sterile environment. The wound was copiously
irrigated with at least 1000 mL of normal saline and
local hemostasis was achieved by a combination of direct
pressure and/or topical thrombin. The wound was
measured and the dimensions documented. All donor
sites for patients in this study were from the anterior
aspect of the ipsilateral thigh (Fig. 1).
Marcaine 0.5% plain was infiltrated in the subcuta-
neous tissue surrounding the donor site and the
appropriately sized area was prepped with sterile mineral
oil to enhance gliding of the dermatome. The donor
STSG site was then harvested utilizing a power derma-
tome set to 0.018 inch thickness and a width of two to
four inches. For larger recipient areas, additional passes
of the dermatome were made as needed in the same
manner. The donor site was dressedwith povidone-iodine
soaked non-adherent gauze and sterile dry dressing. The
STSG was then meshed in a 1:1.5 ratio and applied
directly to the wound bed taking care to smooth any
wrinkles and allow maximum apposition of the graft with
the wound surface (Fig. 2). The STSG was secured with
staples around the edges under minimal tension and a
non-adherent dressing was placed directly over the graft
surface. In order to minimize graft migration and limit
shear forces, a bolster dressing consisting of the foam
portion of a surgical scrub brush and multiple layers of
cast padding were secured firmly over the STSG (Fig. 3).
All patients were placed in a bulky splint until after the
first post-operative visit. The patients were followed
clinically at two weeks post-operatively and then on a
weekly basis for dressing changes and to assess healing
progress. One week follow-up intervals were chosen in
order to allow a quantifiable degree of healing to occur
between clinic visits. Dressing changes consisted of re-
application of the bolster dressing roll gauze with
continuation of the short leg cast or boot. Once healed,
patients were seen in the outpatient clinic every four
weeks until a minimum of 6 months follow up from the
time of STSG application (Figs 4A4G).
The frequencies and mean time to healing were calcu-
lated for all variables of interest. Each variable was
analyzed for healing time using a two-sample independent
t-test. Analysis of variance (ANOVA) tests were also used
to compare healing times. P values of less than 0.05 were
considered significant.
Results
A total of 107 consecutive diabetic patients met the
inclusion criteria for this study ranging in age from 28
to 88 years (average age, 59.1). All 107 patients were
Fig. 1. Donor site from anterior thigh following harvesting of
STSG.
Fig. 2. Graft site with STSG meshed, smoothed, and secured
STSG covered with non-adherent dressing in place with staples.
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and-seven STSG were applied in total, with 29/107
(27.1%) to the right foot, 28/107 (26.2%) to the left
foot, 25/107 (23.4%) to the right leg and 25/107 (23.4%)
to the left leg. Six patients (5.6%) were current smokers,
two (1.9%) admitted to current chewing tobacco use, and
three patients (2.8%) admitted to IV drug abuse. Seven
patients (6.5%) had rheumatoid arthritis. Nine
patients (8.4%) had end-stage renal disease, defined as a
glomerular filtration rate B15mL/min, with all nine
patients receiving ongoing dialysis treatment. Three
patients (2.8%) had a significant history of cardiac
disease which included a diagnosis of coronary artery
disease and/or congestive heart failure. Seven patients
(6.5%) had a documented history of peripheral vascular
disease which included at least one abnormal
non-invasive vascular test (ankle-brachial index, transcu-
taneous oximetry, Doppler wave-forms, segmental
pressures, and pulse volume recordings) and/or non-
palpable pedal pulses on examination. All patients with
PVD received a workup by vascular surgery prior to
application of STSG and were deemed to have sufficient
blood supply for healing. In addition, all patients
included in the study were deemed to have adequate
blood flow to heal a STSG before undergoing the
procedure. Twenty-six patients (24.3%) had a history of
hypertension. One patient (0.9%) had a history
of Charcot neuroarthropathy and received a STSG. Sixty
patients (56.1%) had no other comorbidities besides
diabetes mellitus, 29 patients (27.1%) had one comorbid-
ity, and 18 patients (16.8%) had two or more comorbid-
ities in addition to diabetes. Among all patients, the
average starting wound size prior to graft treatment
was 69.3 cm
2. Approximately half the patients (53/107
patients, or 49.5%) had a starting wound area of less
than 50cm
2, 37/107 (34.6%) had a wound area of 50 to







Fig. 4. Fifty-eight year old male with type 2 diabetes mellitus treated for ulceration on the lateral aspect of his ankle. His ulceration
showed no improvement following conservative treatment with compressive dressings and local wound care. Multiple applications of
human ﬁbroblast-derived dermal substitute were also performed with no improvement. After 6 months of treatment, he was taken to
the operating room for an autogenous STSG. (A) Pre-debridement, (B) Post-Debridement, (C) Postoperative day 0, (D) Postoperative
day 10, (E) 4 weeks postoperative, (F) 8 weeks postoperative, (G) 6 months postoperative.
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2, and 17/107 (15.9%) had a wound area greater
than 100cm
2.
The number of weeks to complete wound healing
ranged from 3 to 16 weeks with an average healing time
of 5.1 weeks. The vast majority of patients (97/107, or
90.1%) were completely healed by 6 weeks post-opera-
tively while only four patients (3.7%) required 10 weeks
or more to completely heal (Graph 1). Our analysis
demonstrated that none of the comorbidities or risk
factor variables had an independent effect on time to
complete wound healing (Table 1). Similarly, age, wound
location and wound size each appeared to have had no
effect on time to heal (Table 2). The patients who had
100% graft take had a shorter healing time than those
with graft take of less than 95% (pB0.001) (Table 3).
Those patients with 100% STSG take had a mean healing
time of 4.8 weeks compared to 7.9 weeks for those
patients with less than 95% STSG take (Graph 2).
The range of STSG take percentage among all groups
was between 40 and 100% with a mean take, overall,
of 97%.
Only three of the patients (2.8%) had a complication
with the original STSG. In two patients (1.9%), the STSG
dressing was removed too early and both patients
required re-grafting and eventually healed. The other
patient had underlying osteomyelitis and required revi-
sional resection of the bone and re-grafting which also
eventually healed completely. No patient experienced a
donor site complication. Patients with complications had
a mean time to complete wound healing of 12.0 weeks
compared to 4.9 weeks for patients without complications
(Table 4).
Discussion
Despite success with STSG in surgery and wound care,
there remain relatively few studies addressing its use in
diabetic lower extremity wounds. In our study of diabetic
patients, the mean time to complete wound healing was
Table 1. Time to complete wound healing (n107)
Risk factor N %
Mean weeks
to healing p
Smoking 6 5.6 6.0 0.183
Alcohol use 5 4.7 5.6 0.504
Intravenous drug use 3 2.8 5.0 0.916
Rheumatoid arthritis 7 6.5 5.0 0.869
End stage renal disease 9 8.4 6.1 0.415
Cardiac disease 3 2.8 4.0 0.254
Peripheral vascular disease 7 6.5 5.7 0.325
Charcot neuroarthropathy 1 0.9 4.0 ****
Hypertension 26 24.3 5.2 0.281
Underlying fracture 1 0.9 10.0 ****
Chewing tobacco 2 1.9 4.5 0.614
****Sample size too small for calculation of p value.
Graph 1. Distribution of time to complete wound healing among n107 patients.
Table 2. Time to complete wound healing for patient age,
wound size, and wound location
n%
Mean weeks
to healing P value
Age ]65 41 38.3 5.4 0.179
Age B65 66 61.7 4.9
Wound size B50 cm
2 53 49.5 5.2 0.111
Wound size 50100 cm
2 37 34.6 4.7
Wound size  100 cm
2 17 15.9 5.7
Right foot 29 27.1 4.7 0.319
Right leg 25 23.4 5.4
Left foot 28 26.2 4.9
Left leg 25 23.4 5.4
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comparable to that of other studies of wound healing in
diabetic populations. Recently, Ramanujam et al. retro-
spectively reviewed 83 diabetic patients treated with
STSGs for diabetic foot and ankle wounds and reported
a median time to healing of 6.9 weeks among those
patients without complications (10). Mahmoud et al.
prospectively studied patients with STSG versus conser-
vative wound care for diabetic foot wounds and found a
statistically significant reduction in mean hospital stay
and healing time for those patients treated with STSG
(11). They noted that 62% of all STSG patients had
healed by week eight. Puttirutvong et al. compared the
healing rates of meshed vs non-meshed STSG in 42
patients and found no significant difference (12). The
mean healing time for the meshed group was 19.84 and
20.36 days for the non-meshed group. Most STSG studies
in non-diabetic studies report healing times between 2
and 4 weeks.
Impaired healing in diabetic patients is well-studied
and can be attributed to multiple factors including
impaired macro and microcirculation, peripheral neuro-
pathy, endothelial dysfunction, and poor glycemic control
(1416). One shortcoming of our study is that we did not
quantitatively analyze preoperative glycemic control.
However, Ramanujam et al. did not find a statistically
significant difference in preoperative hemoglobin A1C
levels and healing time, despite high average preoperative
hemoglobin A1C values in their patients (10). Conversely,
a study by Marston found a direct correlation between
hyperglycemia and wound healing. In this study, we
found that the specific preoperative risk factors showed
no effect on healing time (13). Likewise, age, wound size,
and wound location did not seem to have a significant
effect on healing time. Surprisingly, there was no
significant effect of wound size on difference in healing
time. The mean time to healing for those with wound size
 100 cm
2 was 5.7 weeks compared to 4.7 weeks for
wounds 50 to 100 cm
2 and 5.2 weeks for wounds B50
cm
2. Thus, those patients with a wound size between 50
and 100 cm
2 actually healed faster, on average, than those
with a wound size of B50 cm
2.
Patients in our study with complications took longer to
heal by more than 7 weeks on average than those without
complications. Of the three patients who had complica-
tions, two had healing times of 10 weeks and the other
had a healing time of 16 weeks. The mean healing time
for those patients with complications was 12.0 weeks
versus 4.9 weeks for those without complications. Only
one patient among those without complications had a
healing time longer than 7 weeks. Two patients in our
study had the STSG pulled off at 2 weeks by the nursing
facility. Both patients required re-grafting and healed
without further complications by week 10. The other
patient had osteomyelitis of the underlying bone which
required resection. This patient eventually went on
to heal the wound with aggressive local wound care and
re-grafting by week 16. It stands to reason that post-
operative complications such as infection, noncompli-
ance, seroma, swelling and STSG pressure delay healing
time by disruption of the graft and interfering with the
healing process. Likewise, patients who must undergo
revisional surgery would also be expected to have a delay
in healing time. The overall complication rate in our
study was only 2.6%. This is in contrast to several other
studies that have reported higher rates of complications.
Ramanujam et al. reported a post-graft complication rate
of 35% with 16 patients experiencing an infection (10).
Graph 2. Percent graft take and mean healing time




Mean weeks to complete
healing p
100% 79 4.8 B 0.001
9599% 18 5.0
B95% 10 7.9*
*Represents statistical significance from other values.
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complete wound healing in those patients who experi-
enced complications. Similarly, Mahmoud et al. reported
that 38% of their diabetic patients who received a STSG
failed to heal by post-operative week eight (11).
The patients in our study who had less than 95% graft
take had an average healing time of more than 3 weeks
slower than those with a graft take of 100% (7.9 weeks vs
4.8 weeks), and almost 3 weeks slower than those with a
graft take between 95 and 99% (7.9 weeks vs 5 weeks).
Skin graft healing and incorporation is a complex
biological process involving various stages of adherence,
nourishment, revascularization, and final incorporation
(6). Once harvested, the skin graft is deprived of its native
nutrients and blood supply and can only survive by
adherence to the wound bed and diffusion of nutrients
from the underlying vascular supply until revasculariza-
tion occurs. It stands to reason that any mechanical or
biological disruption of this process puts the graft at risk
for failure or prolonged healing. In our study, we took
measures to prevent disruption to the graft by securing it
place with staples and applying a bolster dressing to
minimize shearing or compressive forces. Care was also
taken to prepare the wound bed prior to graft placement
in a manner that wound maximize the probability of
incorporation. The vast majority of our patients (90.7%)
had greater than 95% graft take and, of those, 73.8% had
100% graft take. Only 10 patients (9.3%) had less than
95% graft take, but this group took longer to heal.
Clearly, the amount of graft take is an indication of the
underlying healing process. STSG with poor graft take
can naturally be expected to take significantly longer to
heal.
Our study is only descriptive in nature, therefore other
statistical methods such as tests for association and
regression analysis would likely provide better informa-
tion regarding the effects of each variable of interest as
well as their additive effects on STSG healing times. On
the same note, this study does not take into account
possible interactions among the variables themselves
which can influence the results. A major limitation of
our study was the small sample size. Only having one
patient with Charcot neuroarthropathy, for example, was
inadequate for analysis with respect to healing time.
A larger population size would have allowed more
statistically meaningful analysis of our data. In addition,
our study was retrospective in design which prevented
inclusion of some data (e.g. type of diabetes and
preoperative hemoglobin A1C levels) which might have
been useful. A prospective, multicenter study is needed to
more accurately investigate and determine the effects of
certain risk factors and comorbidities on STSG wound
healing time in the diabetic population.
Conclusion
Our study demonstrated a very low complication rate of
2.8% and an average wound healing time of 5.1 weeks for
all patients who received a STSG for treatment of a
diabetic foot or leg ulcer. None of the patient character-
istics or comorbidities in this study appeared to affect
STSG healing times, but we did find an average increase
in healing time among patients with complications (12.0
weeks) versus those without complications (4.9 weeks).
Finally, in our group of subjects, those patients with
decreased graft take had prolonged healing times. This
underscores the importance of optimizing the STSG for
incorporation by minimizing any mechanical or biologi-
cal barriers to healing. We conclude that autologous
STSG are a safe and reliable alternative for the treatment
of non-healing diabetic foot and leg wounds.
Conflict of interest and funding
The authors have received no funding or benefits from
industry to conduct this literature review.
References
1. Frykberg RG, Zgonis T, Armstrong DG, Driver VR,
Giurini JM, Kravitz SR, et al. Diabetic foot disorders. A clinical
practice guideline (2006 revision). J Foot Ankle Surg 2006; 45:
S166.
2. Vuorisalo S, Venermo M, Lepa ¨ntalo M. Treatment of diabetic
foot ulcers. J Cardiovasc Surg (Torino) 2009; 50: 27591.
3. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N,
Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in
patients with diabetes. Diabetes Care 1999; 22: 3827.
4. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic
foot ulcers. Am J Surg 1998; 176: S510.
5. Mayﬁeld JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM.
Preventive foot care in people with diabetes. Diabetes Care 2003;
26: S789.
6. Chick LR. Brief history and biology of skin grafting. Ann Plast
Surg 1988; 21: 35865.
7. Baumeister S, Dragu A, Jester A, Germann G, Menke H. The
role of plastic and reconstructive surgery within an interdisci-
plinary treatment concept for diabetic ulcers of the foot [Article
in German]. Dtsch Med Wochensch 2004; 129: 67680.
8. Roukis TS, Zgonis T. Skin grafting techniques for soft-tissue
coverage of diabetic foot and ankle wounds. J Wound Care
2005; 14: 1736.
9. Zgonis T, Stapleton JJ, Roukis TS. Advanced plastic surgery
techniques for soft tissue coverage of the diabetic foot. Clin
Podiatr Med Surg 2007; 24: 54768.
Table 4. Patients with complications (n3)
Complication
Number of weeks to
complete healing
STSG pulled off early 10




John J. Anderson et al.
6
(page number not for citation purpose)
Citation: Diabetic Foot & Ankle 2012, 3: 10204 - DOI: 10.3402/dfa.v3i0.1020410. Ramanujam CL, Stapleton JJ, Kilpadi KL, Rodriguez RH,
Jeffries LC, Zgonis T. Split-thickness skin grafts for closure of
diabetic foot and ankle wounds: a retrospective review of 83
patients. Foot Ankle Spec 2010; 3: 23140.
11. Mahmoud SM, Mohamed AA, Mahdi SE, Ahmed ME.
Split-skin graft in the management of diabetic foot ulcers.
J Wound Care 2008; 17: 3036.
12. Puttirutvong P. Meshed skin graft versus split thickness skin
graft in diabetic ulcer coverage. J Med Assoc Thai 2004; 87:
6672.
13. Marston WA. Risk factors associated with healing chronic
diabetic foot ulcers: the importance of hyperglycemia. Ostomy
Wound Manage 2006; 52: 268.
14. Rosenberg CS. Wound healing in the patient with diabetes
mellitus. Nurs Clin North Am 1990; 25: 24761.
15. Fahey TJ III, Sadaty A, Jones WG II, Barber A, Smoller B,
Shires GT. Diabetes impairs the late inﬂammatory response to
wound healing. J Surg Res 1991; 50: 30813.
16. Krishnan ST, Quattrini C, Jeziorska M, Malik RA, Rayman G.
Neurovascular factors in wound healing in the foot skin of type
2 diabetic subjects. Diabetes Care 2007; 30: 305862.
*John J. Anderson




Split thickness skin grafts
Citation: Diabetic Foot & Ankle 2012, 3: 10204 - DOI: 10.3402/dfa.v3i0.10204 7
(page number not for citation purpose)